NeuroBo Pharmaceuticals, Inc. received IRB approval for Phase 2a clinical trial of DA-1241 for NASH treatment, with dosing of first patient expected in September 2023.
AI Assistant
METAVIA INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.